Simon Laban

First Pavlov State Medical University of St. Petersburg — Russia

Medicine · Health Sciences

30h-index5.9kcitations368works6.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(129), Cancer Immunotherapy and Biomarkers(118), Immunotherapy and Immune Responses(83), Lung Cancer Treatments and Mutations(40), Lung Cancer Research Studies(36)

Publications365 total

First-line systemic therapy for hepatocellular carcinoma: new options
Clinical Case in Oncology·2026Open Access
Modern international guidelines for the management of patients after completion of breast cancer treatment: an evidencebased review
Clinical Case in Oncology·2026Open Access
Prognostic value of regional lymph node ratio (LNR) in locally advanced gastric cancer: A single center analysis.
Journal of Clinical Oncology·2026
Evaluation of an HPV16-L1 antibody rapid test for oropharyngeal cancer diagnosis: diagnostic accuracy and challenges in real-world settings
EBioMedicine·2025· 1 citedOpen Access
Identification of marginal zone B cells in head and neck cancer with immunomodulatory characteristics
Journal of Advanced Research·2025Open Access
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma
Frontiers in Oncology·2025Open Access
Co-Stimulatory and Immune Checkpoint Molecule Expression on Peripheral Immune Cells Differs Age Dependently Between Healthy Donors and Patients with Head and Neck Squamous Cell Carcinoma
Cancers·2025· 1 citedOpen Access
1441TiP An open-label, phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)
Annals of Oncology·2025Open Access
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
New England Journal of Medicine·2025· 157 cited
Surgery of T1/2 N0 M0 glottic cancer results in a better laryngeal preservation time compared to radiotherapy in a large German patient cohort
European Archives of Oto-Rhino-Laryngology·2025· 1 citedOpen Access
Immuntherapie von Kopf-Hals-Tumoren
InFo Hämatologie + Onkologie·2025
Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC).
Journal of Clinical Oncology·2025· 7 cited
Abstract CT001: Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 study
Cancer Research·2025· 7 cited
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research·2025· 8 citedOpen Access
Medikamentöse Tumortherapie von Kopf-Hals-Tumoren: zwischen Standardisierung und Personalisierung
HNO·2025· 1 citedOpen Access
Characterization of the adaptive immune response in a mouse model for HPV-positive head and neck squamous cell carcinoma with implications to human disease
Cancer Immunology Immunotherapy·2025· 2 citedOpen Access
Identification of B Cell Subpopulations with Pro- and Anti-Tumorigenic Properties in an Immunocompetent Mouse Model of Head and Neck Squamous Cell Carcinoma
Cells·2024· 1 citedOpen Access
page 1 of 19Next →

Frequent Co-authors

Thomas K. Hoffmann(24), Patrick J. Schuler(21), Cornelia Brunner(19), Marie‐Nicole Theodoraki(16), Johannes Doescher(14), Rainald Knecht(10), Chia‐Jung Busch(7), Malte Kriegs(6), Linda Hofmann(6), Ramin Lotfi(6), Brett Hughes(5), Adrian von Witzleben(5), Matthias Hautmann(5), Edwin K. Jackson(5), S Jeske(5), Richard Greil(4), Gilberto de Castro(4), Thorsten Fuereder(4), Danny Rischin(4), Iane Pinto Figueiredo Lima(4)